Electromed price target raised to $36 from $35 at Roth Capital

Roth Capital raised the firm’s price target on Electromed (ELMD) to $36 from $35 and keeps a Buy rating on the shares. The company’s Q1 results were above expectations and the management reiterated its goal to drive double-digit top-line growth and expanded operating leverage, the analyst tells investors in a research note. The company’s best-in-class high frequency chest wall oscillation device continues to take share in a highly underdiagnosed bronchiectasis market, the firm added.